Trends Watch: August 10, 2017

EisnerAmper’s Trends Watch is a weekly entry to our Alternative Investments Intelligence blog, featuring the views and insights of executives from alternative investment firms. If you’re interested in being featured, please contact Elana Margulies-Snyderman.  

This week, Elana talks to Michael Levas, Co-Founder, Senior Managing Principal & Chief Investment Officer, Asclepius Life Sciences Fund, LP.

What is your outlook for alternative investments?

The outlook for the alternative asset space is extremely promising; reason being is that private equity is continuing to gather assets at an incredible pace across all of the industry sectors, and in particular those sectors which will see an emphasis on M&A.

Why is it in attractive time to invest in life sciences companies?

The life sciences sector is attractive on many levels , but to our team in particular, the pharma industry is one that is slated to grow over 20% per year over the next four years in an already $400 billion per year industry.

What keeps you up at night?

Our business in general keeps me up at night. There are so many aspects in running the type of firm that we have created. And with emphasis in all of the alternative asset classes in one fund, you can understand why it keeps my energy levels screaming at a furious pace and keeps me from sleeping well at night. (But I would not have it any other way!!!)